Perkin-Elmer Acquires 14.5% Stake In Tecan

24 December 1997

Perkin-Elmer Corp said it has entered into a definitive agreement toacquire 14.5% of Tecan AG, a leader in automating systems for life science and diagnostic markets, based in Switzerland. The acquisition gives P-E approximately 52% of voting rights in Tecan.

Tecan has market capitalization of approximately 470 million Swiss francs ($328.1 million) and trades on the Swiss stock exchange. P-E is to pay cash for the shares, although other financial terms were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight